Hoth Therapeutics Announces Acceptance to Present HT-ALZ Proof-of-Concept Alzheimer’s Disease Data at the 2022 Alzheimer’s Association International Conference
Dr. Yuede will present the preclinical Alzheimer’s disease mouse model data for exploring HT-ALZ for the treatment of Alzheimer’s disease NEW YORK, April 12, 2022 /PRNewswire/ — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced…
Comments Off on Hoth Therapeutics Announces Acceptance to Present HT-ALZ Proof-of-Concept Alzheimer’s Disease Data at the 2022 Alzheimer’s Association International Conference